EU/3/12/1044

About

A marketing authorisation application for this medicine was withdrawn on 16 May 2014.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the sponsor.

On 10 September 2012, orphan designation (EU/3/12/1044) was granted by the European Commission to Endocyte Europe B.V., the Netherlands, for folic acid to be used with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine for the diagnosis of positive folate-receptor status in ovarian cancer.

Key facts

Active substance
Folic acid to be used with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine
Medicine name
Neocepri
Disease / condition
Diagnosis of positive folate-receptor status in ovarian cancer
Date of first decision
10/09/2012
Outcome
Withdrawn
EU designation number
EU/3/12/1044

Review of designation

A marketing authorisation application for this medicine was withdrawn on 16 May 2014.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the sponsor.

Sponsor's contact details

Endocyte Europe B.V.
Prins Bernhardplein 200
1097 JB Amsterdam
The Netherlands
Telephone: +31 20 521 4777
Telefax: +31 20 521 4821
E-mail: tjalling.huisman@intertrustgroup.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating